Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by ANALIAS00on Jan 04, 2022 1:03pm
134 Views
Post# 34282189

RE:RE:My opinion

RE:RE:My opinion
Investing in biotechnologies is close to be like investigating in minings. It is a very speculative investment. As a "wise" and "smart" invester we should not be frustrated if investing in biotechnologies since we should be investing a very low percentage of our money in this risky industry. So, if you are frustrated, it just mean that you had invested to much of your money. Am I frustrated ? No. I am very VERY frustrated !! :o))

That being said, I really think THTX should and could be doing better easily for shareholders.
And I agree that we missed an opportunity to kick out a board member last year to at least send a signal that we do care about their lack of communication and leadership in promiting SP and that we may again signal our "frustration" in the future.
At this point, THTX is like any other biotech that will take actions to survive the future and diluting will always be an option for them of course. And like all others they will hope that their research and technology will one day pay off. It may happen to a level that will allow them to only survive yeat after year or they may have modest but decend success. But we here all hope that they one day hit an homerun. Since no news were provided in december by THTX I will lower my expectations to avoid more frustration in 2022.

Happy new year to everyone :o)
<< Previous
Bullboard Posts
Next >>